GlassScriptPhysician profile
Wesley A Vaughan
NPI 1609137330
$3,629.82
in general payments reported to CMS, 2019-2025
31 companies · $112 in 2025
The $112 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $183 · 2020: $216 · 2021: $1,044 · 2022: $998 · 2023: $633 · 2024: $443 · 2025: $112.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,188.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $805.40 | 2019-2023 | Liletta, Ubrelvy, Lo Loestrin Fe |
| Gynesonics, INC. | $411.95 | 2021-2022 | |
| Organon LLC | $391.86 | 2021-2024 | Nexplanon, Nuvaring |
| Mayne Pharma Commercial LLC | $318.30 | 2021-2024 | |
| Sage Therapeutics, LLC | $229.40 | 2020-2025 | Zurzuvae |
| Bayer Healthcare Pharmaceuticals INC. | $217.29 | 2019-2023 | |
| Astellas Pharma US INC | $196.09 | 2022-2024 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $151.18 | 2019-2025 | Thinprep 2000 Processor, Aptima |
| Agile Therapeutics, INC. | $113.31 | 2021-2024 | Twirla |
| Pfizer INC. | $99.46 | 2019-2023 | |
| Therapeuticsmd, INC. | $92.68 | 2019-2021 | |
| Minerva Surgical, INC | $86.78 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $76.39 | 2021-2022 | |
| Exeltis, USA INC. | $50.48 | 2021-2023 | Slynd |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.81 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicem INC. | $43.37 | 2020 | |
| Mylan Pharmaceuticals INC. | $34.71 | 2021-2022 | |
| Meditrina | $33.30 | 2023-2025 | |
| Avion Pharmaceuticals | $30.42 | 2021-2022 | |
| Evofem Biosciences, INC. | $28.36 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $21.84 | 2022 | |
| Supernus Pharmaceuticals, INC. | $20.12 | 2025 | Qelbree |
| Duchesnay USA Incorporated | $16.64 | 2019 | |
| Alydia Health | $15.65 | 2021 | |
| Millicent US INC | $15.09 | 2023 | Intrarosa |
| Mission Pharmacal Company | $14.13 | 2021 | |
| Scynexis, INC. | $13.95 | 2022 | |
| Roche Diagnostics Corporation | $13.60 | 2020 | |
| Allergan, INC. | $13.41 | 2019 | |
| Amgen INC. | $12.66 | 2021 | |
| Myovant Sciences INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Vaughan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.